相关实验视频

Updated: Jan 10, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

造血型二乙酸-4缺乏促进M2巨的两极分化,减轻动脉样硬化

Yuqi Zhou¹, Takeshi Matsumura², Sho Saito¹

¹Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Biochemical and biophysical research communications

|November 28, 2025

概括

免疫细胞中的二乙酶-4 (DPP4) 缺乏通过促进抗炎M2巨细胞减少动脉样硬化. 这一发现表明DPP4是炎症性心血管疾病的潜在治疗点.

科学领域:

免疫学免疫学免疫学
心血管生物学心血管生物学
分子医学是分子医学.

背景情况:

动脉样硬化是一种慢性炎症性疾病,其中巨细胞两极分化是关键.
二乙酶-4 (DPP4) 与血管炎症有关,但其具体作用尚不清楚.

研究的目的:

研究Dpp4缺陷,特别是造血细胞,对巨细胞极化和动脉样硬化进展的影响.

主要方法:

使用了Apoe-knockout (ApoeKO) 和Apoe/Dpp4-双击的小鼠.
采用骨髓移植模型来评估系统性和骨髓特异性Dpp4缺乏症.
在体外和体内分析了巨细胞偏振 (M1/M2标记物).
在ApoeKO小鼠中量化了大动脉损伤区域和巨细胞透.

主要成果:

巨细胞中的Dpp4缺乏在IL-4刺激时增强了M2极化 (例如Arg1,Ym1).
在ApoeKO小鼠中,全身和造血Dpp4缺乏症显著减少了大动脉损伤区域和巨细胞透.
在体内研究显示,大动脉中M2相关基因表达和IL-4水平增加,M1标记物没有变化.
造血Dpp4缺乏抑制动脉样硬化独立于代谢变化.

结论:

造血DPP4是巨细胞极化和动脉样硬化的关键调节者.
Dpp4 缺乏会促进一种抗炎M2 巨细胞表型,减轻动脉样硬化.
抑制DPP4代表了炎症性心血管疾病的潜在治疗策略.

关键词:

动脉样硬化是一种动脉样硬化.双基酸酶-4的二基-4的二基-4的二基-4的二基-4的炎症炎症是一种炎症.在M2巨细胞中.巨细胞的两极分化

更多相关视频

Depletion and Reconstitution of Macrophages in Mice

Depletion and Reconstitution of Macrophages in Mice

Published on: August 1, 2012

Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis

Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis

Published on: November 28, 2015

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

Inflammation

Inflammation